Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic evolution of human respiratory syncytial virus during a decade (2013-2023), bridging the path to monoclonal antibody surveillance

  • Piñana, Maria|||0000-0002-4766-2613
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Andrés, Cristina|||0000-0002-3200-0895
  • Vila, Jorgina|||0000-0001-9715-0627
  • Creus-Costa, Anna|||0000-0002-9861-5550
  • Prats-Méndez, Ignasi
  • Arnedo Muñoz, Maria
  • Saubi, Narcis|||0000-0001-5493-1044
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Quer, Josep|||0000-0003-0014-084X
  • González-López, Juanjo|||0000-0003-2419-5909
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Martínez-Urtaza, Jaime|||0000-0001-6219-0418
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
Objectives: This study investigated the prevalence, genetic diversity, and evolution of human respiratory syncytial virus (HRSV) in Barcelona from 2013 to 2023. Methods: Respiratory specimens from patients with RTI suspicion at Hospital Universitari Vall d'Hebron were collected from October 2013 to May 2023 for laboratory-confirmation of respiratory viruses. Next-generation sequencing was performed in randomly-selected samples with Illumina technology. Phylogenetic analyses of whole genome sequences were performed with BEAST v1.10.4. Signals of selection and evolutionary pressures were inferred by population dynamics and evolutionary analyses. Mutations in major surface proteins were genetic and structurally characterised, emphasizing those within antigenic epitopes. Results: Analyzing 139,625 samples, 5.3% were HRSV-positive (3008 HRSV-A, 3882 HRSV-B, 56 HRSV-A and -B, and 495 unsubtyped HRSV), with a higher prevalence observed in the paediatric population. Pandemic-related shifts in seasonal patterns returned to normal in 2022-2023. A total of 198 whole-genome sequences were obtained for HRSV-A (6.6% of the HRSV-A positive samples) belonging to GA2.3.5 lineage. For HRSV-B, 167 samples were sequenced (4.3% of the HRSV-B positive samples), belonging to GB5.0.2, GB5.0.4a and GB5.0.5a. HRSV-B exhibited a higher evolution rate. Post-SARS-CoV-2 pandemic, both subtypes showed increased evolutionary rates and decreased effective population size initially, followed by a sharp increase. Analyses indicated negative selective pressure on HRSV. Mutations in antigenic epitopes, including S276N and M274I in palivizumab-targeted site II, and I206M, Q209R, and S211N in nirsevimab-targeted site Ø, were identified. Discussion: Particularly in the context of the large-scale use in 2023-2024 season of nirsevimab, continuous epidemiological and genomic surveillance is crucial.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): A long-term, clinical, epidemiologic and economic study

  • Vila Soler, Jorgina
  • Lera Carballo, Esther
  • Piñana Moro, Maria
  • Rello Saltor, Victoria
  • Tobeña Rue, Marc
  • Balcells Ramirez, Joan
  • Benítez Díaz, Zaira
  • Aller Hernández, Marta Beatriz
  • Muñoz Gallarin, Rosario
  • Vázquez, Ana
  • Rodrigo Gonzalo de Liria, Carlos
  • Soler-palacín, Pere
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Cost of illness; Hospitalization; Viruses, Cost de la malaltia; Hospitalització; Virus, Coste de la enfermedad; Hospitalización; Virus, Background Viral lower respiratory tract infections (LRTI) are the leading cause of hospitalization in children. In Catalonia (Spain), information is scarce about the burden of viral LRTIs in paediatric hospitalizations. The aim of this study is to describe epidemiological, clinical, virological and economic features of paediatric hospitalizations due to viral LRTI. Methods From October 2012 to December 2020, children aged <16 years admitted to a tertiary paediatric hospital in Catalonia (Spain) with confirmed viral LRTI were included in the study. Virus seasonality, prevalence, age and sex distribution, clinical characteristics, hospital costs and bed occupancy rates were determined. Results A total of 3,325 children were included (57.17% male, 9.44% with comorbidities) accounting for 4056 hospitalizations (32.47% ≤ 12 months): 53.87% with wheezing/asthma, 37.85% with bronchiolitis and 8.28% with pneumonia. The most common virus was respiratory syncytial virus (RSV) (52.59%). Influenza A was associated with pneumonia (odds ratio [OR] 7.75) and caused longer hospitalizations (7 ± 31.58 days), while RSV was associated with bronchiolitis (OR 6.62) and was the most frequent reason for admission to the paediatric intensive care unit (PICU) (11.23%) and for respiratory support (78.76%). Male sex, age ≤12 months, chronic conditions and bronchiolitis significantly increased the odds of PICU admission. From October to May, viral LRTIs accounted for 12.36% of overall hospital bed days. The total hospitalization cost during the study period was €16,603,415. Conclusions Viral LRTIs are an important cause of morbidity, hospitalization and PICU admission in children. The clinical burden is associated with significant bed occupancy and health-care costs, especially during seasonal periods., This work was partially supported by the Spanish National R + D + I Plan 2008–2011 and by the Carlos III Health Institute, the Subdirectorate-General of Networks and Cooperative Research Centers, the Spanish Ministry of Economy and Competitiveness, the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), and by the Health Research Fund, the Spanish Ministry of Economy and Competitiveness (grants FIS PI14/01838 and FIS PI18/00685), and the European Regional Development Fund (ERDF). Editorial assistance for revision of the English language and edition of the manuscript was provided by Vanessa Marfil, medical writer from MSC (Spain) and funded by Sanofi.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain

  • Abanto Marín, Michel
  • Vila, Jorgina
  • Saubi, Narcis
  • Piñana, María
  • González-Sánchez, Alejandra
  • Esperalba, Juliana
  • Codina, María Gema
  • Pumarola Suñe, Tomàs
  • Antón Pagarolas, Andrés
  • Creus-Costa, Anna
  • Andrés Vergés, Cristina
Epidemiology; Human metapneumovirus; Whole-genome sequencing, Epidemiologia; Metapneumovirus humà; Seqüenciació del genoma complet, Epidemiología; Metapneumovirus humano; Secuenciación del genoma completo, Background Human metapneumovirus (HMPV) is an important aetiologic agent of respiratory tract infection (RTI). This study aimed to describe the prevalence, genetic diversity, and evolutionary dynamics of HMPV. Methods Laboratory-confirmed HMPV were characterised based on partial-coding G gene sequences with MEGA.v6.0. WGS was performed with Illumina, and evolutionary analyses with Datamonkey and Nextstrain. Results HMPV prevalence was 2.5%, peaking in February-April and with an alternation in the predominance of HMPV-A and –B until the emergence of SARS-CoV-2, not circulating until summer and autumn-winter 2021, with a higher prevalence and with the almost only circulation of A2c111dup. G and SH proteins were the most variable, and 70% of F protein was under negative selection. Mutation rate of HMPV genome was 6.95 × 10-4 substitutions/site/year. Conclusion HMPV showed a significant morbidity until the emergence of SARS-CoV-2 pandemic in 2020, not circulating again until summer and autumn 2021, with a higher prevalence and with almost the only circulation of A2c111dup, probably due to a more efficient immune evasion mechanism. The F protein showed a very conserved nature, supporting the need for steric shielding. The tMRCA showed a recent emergence of the A2c variants carrying duplications, supporting the importance of virological surveillance., This study was supported by the European Regional Development Fund (ERDF) "A way to achieve Europe", Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0003], and supported by the Health Research Fund, Spanish Ministry of Economy and Competitiveness [Grant FIS PI18/00685].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genomic evolution of human respiratory syncytial virus during a decade (2013–2023): bridging the path to monoclonal antibody surveillance

  • Prats Mendez, Ignasi
  • Nadal-Barón, Patricia
  • Piñana, María
  • González-Sánchez, Alejandra
  • Vila, Jorgina
  • Saubi, Narcis
  • Esperalba, Juliana
  • Rando Segura, Ariadna
  • QUER, JOSEP
  • González-López, Juan José
  • Pumarola Suñe, Tomàs
  • Antón Pagarolas, Andrés
  • Creus-Costa, Anna
  • Andrés Vergés, Cristina
  • Arnedo-Muñoz, Maria
  • Larrosa, María Nieves
  • Soler-Palacin, Pere
Evolution; Human respiratory syncytial virus; Monoclonal antibodies, Evolución; Virus respiratorio sincitial humano; Anticuerpos monoclonicos, Evolució; Virus respiratori sincitial humà; Anticossos monoclonals, Objectives This study investigated the prevalence, genetic diversity, and evolution of human respiratory syncytial virus (HRSV) in Barcelona from 2013 to 2023. Methods Respiratory specimens from patients with RTI suspicion at Hospital Universitari Vall d′Hebron were collected from October 2013 to May 2023 for laboratory-confirmation of respiratory viruses. Next-generation sequencing was performed in randomly-selected samples with Illumina technology. Phylogenetic analyses of whole genome sequences were performed with BEAST v1.10.4. Signals of selection and evolutionary pressures were inferred by population dynamics and evolutionary analyses. Mutations in major surface proteins were genetic and structurally characterised, emphasizing those within antigenic epitopes. Results Analyzing 139,625 samples, 5.3% were HRSV-positive (3008 HRSV-A, 3882 HRSV-B, 56 HRSV-A and -B, and 495 unsubtyped HRSV), with a higher prevalence observed in the paediatric population. Pandemic-related shifts in seasonal patterns returned to normal in 2022–2023. A total of 198 whole-genome sequences were obtained for HRSV-A (6.6% of the HRSV-A positive samples) belonging to GA2.3.5 lineage. For HRSV-B, 167 samples were sequenced (4.3% of the HRSV-B positive samples), belonging to GB5.0.2, GB5.0.4a and GB5.0.5a. HRSV-B exhibited a higher evolution rate. Post-SARS-CoV-2 pandemic, both subtypes showed increased evolutionary rates and decreased effective population size initially, followed by a sharp increase. Analyses indicated negative selective pressure on HRSV. Mutations in antigenic epitopes, including S276N and M274I in palivizumab-targeted site II, and I206M, Q209R, and S211N in nirsevimab-targeted site Ø, were identified. Discussion Particularly in the context of the large-scale use in 2023–2024 season of nirsevimab, continuous epidemiological and genomic surveillance is crucial., This study was supported by the European Development Regional Fund (ERDF) “A way to achieve Europe”, Spanish Ministry of Economy and Competitiveness [Grant FIS PI18/00685], and by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB 2021), CIBERINFEC, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain), A long-term, clinical, epidemiologic and economic study

  • Vila, Jorgina|||0000-0001-9715-0627
  • Lera, Esther
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • Rello-Saltor, Victoria|||0000-0002-7545-6462
  • Tobeña Rue, Marcos|||0009-0004-0798-3238
  • Balcells Ramírez, Joan|||0000-0002-8341-6508
  • Benítez-Díaz, Zaira
  • Aller Hernández, Marta Beatriz|||0000-0002-3344-2329
  • Muñoz, Rosario
  • Vázquez Fariñas, Ana|||0000-0001-6732-1667
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
Viral lower respiratory tract infections (LRTI) are the leading cause of hospitalization in children. In Catalonia (Spain), information is scarce about the burden of viral LRTIs in paediatric hospitalizations. The aim of this study is to describe epidemiological, clinical, virological and economic features of paediatric hospitalizations due to viral LRTI. From October 2012 to December 2020, children aged <16 years admitted to a tertiary paediatric hospital in Catalonia (Spain) with confirmed viral LRTI were included in the study. Virus seasonality, prevalence, age and sex distribution, clinical characteristics, hospital costs and bed occupancy rates were determined. A total of 3,325 children were included (57.17% male, 9.44% with comorbidities) accounting for 4056 hospitalizations (32.47% ≤ 12 months): 53.87% with wheezing/asthma, 37.85% with bronchiolitis and 8.28% with pneumonia. The most common virus was respiratory syncytial virus (RSV) (52.59%). Influenza A was associated with pneumonia (odds ratio [OR] 7.75) and caused longer hospitalizations (7 ± 31.58 days), while RSV was associated with bronchiolitis (OR 6.62) and was the most frequent reason for admission to the paediatric intensive care unit (PICU) (11.23%) and for respiratory support (78.76%). Male sex, age ≤12 months, chronic conditions and bronchiolitis significantly increased the odds of PICU admission. From October to May, viral LRTIs accounted for 12.36% of overall hospital bed days. The total hospitalization cost during the study period was €16,603,415. Viral LRTIs are an important cause of morbidity, hospitalization and PICU admission in children. The clinical burden is associated with significant bed occupancy and health-care costs, especially during seasonal periods.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased RSV-A Bronchiolitis Severity in RSV-Infected Children Admitted to a Reference Center in Catalonia (Spain) Between 2014 and 2018

  • Vila, Jorgina|||0000-0001-9715-0627
  • Lera, Esther
  • Peremiquel-Trillas, Paula
  • Andrés, Cristina|||0000-0002-3200-0895
  • Martínez, Laia
  • Barceló, Irene
  • Carsi, Ariadna
  • Balcells Ramírez, Joan|||0000-0002-8341-6508
  • Rodrigo Pendas, Jose Angel|||0000-0003-0400-8766
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
Between 2014 and 2018, we evaluated the severity of 687 cases of bronchiolitis caused by respiratory syncytial virus (RSV) in Catalonia, Spain. Compared to RSV-B, RSV-A cases required intensive care (adjusted relative risk (aRR) = 1.44, p < 0.01) and respiratory support (aRR = 1.07, p < 0.01) more often; hospital stay was one day longer (p < 0.01). Subgroup identification may aid clinical evaluation and seasonal healthcare planning.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): A long-term, clinical, epidemiologic and economic study

  • Vila Soler, Jorgina
  • Lera Carballo, Esther
  • Piñana Moro, Maria
  • Rello Saltor, Victoria
  • Tobeña Rue, Marc
  • Balcells Ramirez, Joan
  • Benítez Díaz, Zaira
  • Aller Hernández, Marta Beatriz
  • Muñoz Gallarin, Rosario
  • Vázquez, Ana
  • Rodrigo Gonzalo de Liria, Carlos
  • Soler Palacín, Pere
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Cost of illness; Hospitalization; Viruses, Cost de la malaltia; Hospitalització; Virus, Coste de la enfermedad; Hospitalización; Virus, Background Viral lower respiratory tract infections (LRTI) are the leading cause of hospitalization in children. In Catalonia (Spain), information is scarce about the burden of viral LRTIs in paediatric hospitalizations. The aim of this study is to describe epidemiological, clinical, virological and economic features of paediatric hospitalizations due to viral LRTI. Methods From October 2012 to December 2020, children aged <16 years admitted to a tertiary paediatric hospital in Catalonia (Spain) with confirmed viral LRTI were included in the study. Virus seasonality, prevalence, age and sex distribution, clinical characteristics, hospital costs and bed occupancy rates were determined. Results A total of 3,325 children were included (57.17% male, 9.44% with comorbidities) accounting for 4056 hospitalizations (32.47% ≤ 12 months): 53.87% with wheezing/asthma, 37.85% with bronchiolitis and 8.28% with pneumonia. The most common virus was respiratory syncytial virus (RSV) (52.59%). Influenza A was associated with pneumonia (odds ratio [OR] 7.75) and caused longer hospitalizations (7 ± 31.58 days), while RSV was associated with bronchiolitis (OR 6.62) and was the most frequent reason for admission to the paediatric intensive care unit (PICU) (11.23%) and for respiratory support (78.76%). Male sex, age ≤12 months, chronic conditions and bronchiolitis significantly increased the odds of PICU admission. From October to May, viral LRTIs accounted for 12.36% of overall hospital bed days. The total hospitalization cost during the study period was €16,603,415. Conclusions Viral LRTIs are an important cause of morbidity, hospitalization and PICU admission in children. The clinical burden is associated with significant bed occupancy and health-care costs, especially during seasonal periods., This work was partially supported by the Spanish National R + D + I Plan 2008–2011 and by the Carlos III Health Institute, the Subdirectorate-General of Networks and Cooperative Research Centers, the Spanish Ministry of Economy and Competitiveness, the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), and by the Health Research Fund, the Spanish Ministry of Economy and Competitiveness (grants FIS PI14/01838 and FIS PI18/00685), and the European Regional Development Fund (ERDF). Editorial assistance for revision of the English language and edition of the manuscript was provided by Vanessa Marfil, medical writer from MSC (Spain) and funded by Sanofi.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain

  • Abanto Marín, Michel
  • Vila, Jorgina
  • Saubi, Narcis
  • Piñana, María
  • González-Sánchez, Alejandra
  • Esperalba, Juliana
  • Codina, María Gema
  • Pumarola Suñe, Tomàs
  • Antón Pagarolas, Andrés
  • Creus-Costa, Anna
  • Andrés Vergés, Cristina
Epidemiology; Human metapneumovirus; Whole-genome sequencing, Epidemiologia; Metapneumovirus humà; Seqüenciació del genoma complet, Epidemiología; Metapneumovirus humano; Secuenciación del genoma completo, Background Human metapneumovirus (HMPV) is an important aetiologic agent of respiratory tract infection (RTI). This study aimed to describe the prevalence, genetic diversity, and evolutionary dynamics of HMPV. Methods Laboratory-confirmed HMPV were characterised based on partial-coding G gene sequences with MEGA.v6.0. WGS was performed with Illumina, and evolutionary analyses with Datamonkey and Nextstrain. Results HMPV prevalence was 2.5%, peaking in February-April and with an alternation in the predominance of HMPV-A and –B until the emergence of SARS-CoV-2, not circulating until summer and autumn-winter 2021, with a higher prevalence and with the almost only circulation of A2c111dup. G and SH proteins were the most variable, and 70% of F protein was under negative selection. Mutation rate of HMPV genome was 6.95 × 10-4 substitutions/site/year. Conclusion HMPV showed a significant morbidity until the emergence of SARS-CoV-2 pandemic in 2020, not circulating again until summer and autumn 2021, with a higher prevalence and with almost the only circulation of A2c111dup, probably due to a more efficient immune evasion mechanism. The F protein showed a very conserved nature, supporting the need for steric shielding. The tMRCA showed a recent emergence of the A2c variants carrying duplications, supporting the importance of virological surveillance., This study was supported by the European Regional Development Fund (ERDF) "A way to achieve Europe", Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0003], and supported by the Health Research Fund, Spanish Ministry of Economy and Competitiveness [Grant FIS PI18/00685].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Genomic evolution of human respiratory syncytial virus during a decade (2013–2023): bridging the path to monoclonal antibody surveillance

  • Prats Mendez, Ignasi
  • Nadal-Barón, Patricia
  • Piñana, María
  • González-Sánchez, Alejandra
  • Vila, Jorgina
  • Saubi, Narcis
  • Esperalba, Juliana
  • Rando Segura, Ariadna
  • QUER, JOSEP
  • González-López, Juan José
  • Pumarola Suñe, Tomàs
  • Antón Pagarolas, Andrés
  • Creus-Costa, Anna
  • Andrés Vergés, Cristina
  • Arnedo-Muñoz, Maria
  • Larrosa, María Nieves
  • Soler-Palacin, Pere
Evolution; Human respiratory syncytial virus; Monoclonal antibodies, Evolución; Virus respiratorio sincitial humano; Anticuerpos monoclonicos, Evolució; Virus respiratori sincitial humà; Anticossos monoclonals, Objectives This study investigated the prevalence, genetic diversity, and evolution of human respiratory syncytial virus (HRSV) in Barcelona from 2013 to 2023. Methods Respiratory specimens from patients with RTI suspicion at Hospital Universitari Vall d′Hebron were collected from October 2013 to May 2023 for laboratory-confirmation of respiratory viruses. Next-generation sequencing was performed in randomly-selected samples with Illumina technology. Phylogenetic analyses of whole genome sequences were performed with BEAST v1.10.4. Signals of selection and evolutionary pressures were inferred by population dynamics and evolutionary analyses. Mutations in major surface proteins were genetic and structurally characterised, emphasizing those within antigenic epitopes. Results Analyzing 139,625 samples, 5.3% were HRSV-positive (3008 HRSV-A, 3882 HRSV-B, 56 HRSV-A and -B, and 495 unsubtyped HRSV), with a higher prevalence observed in the paediatric population. Pandemic-related shifts in seasonal patterns returned to normal in 2022–2023. A total of 198 whole-genome sequences were obtained for HRSV-A (6.6% of the HRSV-A positive samples) belonging to GA2.3.5 lineage. For HRSV-B, 167 samples were sequenced (4.3% of the HRSV-B positive samples), belonging to GB5.0.2, GB5.0.4a and GB5.0.5a. HRSV-B exhibited a higher evolution rate. Post-SARS-CoV-2 pandemic, both subtypes showed increased evolutionary rates and decreased effective population size initially, followed by a sharp increase. Analyses indicated negative selective pressure on HRSV. Mutations in antigenic epitopes, including S276N and M274I in palivizumab-targeted site II, and I206M, Q209R, and S211N in nirsevimab-targeted site Ø, were identified. Discussion Particularly in the context of the large-scale use in 2023–2024 season of nirsevimab, continuous epidemiological and genomic surveillance is crucial., This study was supported by the European Development Regional Fund (ERDF) “A way to achieve Europe”, Spanish Ministry of Economy and Competitiveness [Grant FIS PI18/00685], and by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB 2021), CIBERINFEC, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU.